SciLifeLab The Svedberg seminar series, Daniel Globisch
Monday December 5
SciLifeLab, Department of Medicinal Chemistry, Uppsala University
Assistant Professor Daniel Globisch defended his PhD thesis in Organic Chemistry in the group of Professor Thomas Carell at the Ludwig-Maximilians-University of Munich in 2011. His research focused on the synthesis and mass spectrometric quantification of natural modified transfer-RNA nucleosides and the recently discovered epigenetic DNA marker 5-hydroxymethylcytosine. To extend his expertise and skills in Chemical Biology, he joined the laboratory of Professor Kim D. Janda at The Scripps Research Institute to develop new strategies for the inhibition of bacterial Quorum Sensing holding a research grant from the German Academic Exchange Service (DAAD) in 2011. During his postdoctoral research Dr. Globisch also discovered a small molecule urine biomarker using a metabolomics mining approach for the neglected tropical disease onchocerciasis within the Worm Institute for Research and Medicine (WIRM). He started his independent research at Uppsala University by building up his laboratory in September 2015 as a Science For Life Laboratory Fellow in the Division of Analytical Pharmaceutical Chemistry at the Department of Medicinal Chemistry.
Advanced approaches for the discovery of small molecule biomarkers
Pancreatic cancer is one of the most lethal cancer types worldwide with very low survival rates due to the absence of sensitive and reliable diagnostic tools for an early detection. The discovery of unknown early-stage biomarkers for both cancer types is urgently required and the impact of host-microbiome interactions for the development of pancreatic cancer on a molecular level is still unknown. We are developing new metabolite-analyzing methodologies at the interface of Chemistry and Biology to overcome limitations in mass spectrometry-based disease-specific metabolome analysis. These methodologies represent a new strategy for small molecule biomarker discovery with a focus on the interaction between gut microbiota and the human host to gain crucial insights in the development of pancreatic cancer. Validated specific early-stage biomarkers are a crucial first step for the development of new diagnostics, which would allow for improved and more efficient therapeutic interventions.
Host: Jonas Bergquist